Who: GlaxoSmithKline
With: Actelion
What: $3.25B partnership
Summary: In July, GlaxoSmithKline agreed top pay Acetlion â‚£150 million up front and up to â‚£415 million more depending on Phase III data for its insomnia drug almorexant. Actelion could get another â‚£2.7 billion in additional milestone payments based on almorexant results for insomnia and two other major indications. As part of the deal, GSK gets worldwide rights to the drug outside of Japan.